Abrysvo is labelled for use as a single injection ... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.

The US Food and Drug Administration (FDA) has expanded the indication for Pfizer’s respiratory syncytial virus (RSV) vaccine ...

Risks and uncertainties include, among other things, uncertainties regarding the commercial success of ABRYSVO; the uncertainties inherent in research and development, including the ability to ...

After decades of vaccine research by the scientific community and Pfizer, we now have the opportunity to help alleviate the burden of RSV in this high-risk adult population,” ...

Pfizer (PFE) announced that the U.S. FDA has approved Abrysvo, the company’s bivalent RSV prefusion F vaccine, for the prevention of lower respiratory tract disease caused by RSV in individuals ...

Pfizer Inc. PFE announced that the FDA has granted approval for the expanded use of its respiratory syncytial virus (RSV) vaccine, Abrysvo, in adults aged 18-59 years. The vaccine has been ...

After decades of vaccine research by the scientific community and Pfizer, we now have the opportunity to help alleviate the burden of RSV in this high-risk adult population," said Aamir Malik, Chief U ...

(RTTNews) - Pfizer Inc. (PFE) announced that the U.S. Food and Drug Administration approved ABRYSVO (Respiratory Syncytial Virus Vaccine), the company's bivalent RSV prefusion F or RSVpreF vaccine ...

Pfizer Inc. PFE announced that the FDA has granted approval for the expanded use of its respiratory syncytial virus (RSV) vaccine, Abrysvo, in adults aged 18-59 years. The vaccine has been approved ...